21 June 2021 - - UK-based diagnostics and innovative cancer therapies developer Avacta Group plc (AIM: AVCT) has entered into a non-exclusive distribution agreement with life science products provider Calibre Scientific Inc for Avacta's AffiDX SARS-CoV-2 antigen lateral flow test for professional use in the UK and European Economic Area, the company said.

Calibre is a diversified global provider of life science products to the diagnostics, healthcare, research, industrial, and biopharmaceutical communities.

With headquarters in Los Angeles, California, Calibre has a global reach extending to over 100 countries across a wide array of verticals and geographies.

The non-exclusive distribution agreement for Avacta's AffiDX SARS-CoV-2 antigen lateral flow test for professional use covers the UK and EEA. The test will be listed on Calibre's web site and available to be purchased by professional users.

Avacta will continue to focus on developing direct sales opportunities to major corporates and other large scale end users.

The company said it is also in discussion with potential customers in territories outside the UK and EEA, including some of the APAC region, where the additional regulatory approvals required beyond CE marking are minimal.